MedTech Company Precisis Expands with Appointment of Top Executive as New CEO
Heidelberg/Berlin, 03.09.2024 – Heidelberg-based MedTech company PRECISIS GmbH, specializing in neuromodulation therapies, has appointed Karl Stoklosa as its new CEO, effective September 1, 2024. Previously, Stoklosa held various leadership positions at Abbott Laboratories, most recently serving as Director of Global Marketing for the CRM Division. He succeeds Angela Liedler, who has successfully led the company since its early years. Founded in 2014, PRECISIS has established itself as an innovator with the EASEE® brain pacemaker, a minimally invasive solution for the treatment of epilepsy. The company combines cutting-edge technology with a deep understanding of the needs of patients and healthcare professionals. With a clear focus on core markets in Europe and the USA, PRECISIS aims to improve the quality of life for people worldwide. Stoklosa's appointment marks the beginning of a new phase for the Heidelberg-based company, which has already established itself with the EASEE® brain pacemaker.
German Innovation Company on a Path to Expansion
"With Karl Stoklosa at the helm, we are setting a clear course for the future of PRECISIS. He brings not only extensive international experience but also the vision and determination needed to take our company to the next level," emphasized Dr. Felix Baader, Chairman of the Advisory Board of PRECISIS GmbH. "The MedTech industry is evolving rapidly, and we are confident that Stoklosa will drive PRECISIS's momentum forward and inspire our team." This leadership change marks the end of an era characterized by the outstanding work of Angela Liedler. Under her leadership, the innovative EASEE® brain pacemaker was successfully brought to market—a milestone in epilepsy treatment. "Her entrepreneurial foresight and dedication remain an inspiration to all of us," Baader added.
There's a lot to do: Top Executive Becomes New CEO
Karl Stoklosa expressed his enthusiasm for his new role: "It is a privilege to take on the leadership of PRECISIS at such an exciting time. Our goal is to improve the quality of life for millions of epilepsy patients worldwide through groundbreaking technologies. I am determined to further enhance PRECISIS's innovative strength and set new benchmarks in neuromodulation." Stoklosa is a renowned global executive known for consistently steering towards success. His career has been marked by successful strategies and innovations, most recently as Director of Global Marketing at Abbott Laboratories, where he made significant contributions to the CRM Division. He holds an MBA from the prestigious University of Chicago Booth School of Business.
About Precisis
PRECISIS GmbH is an innovative medical technology company based in Heidelberg, specializing in the development and marketing of neuromodulation therapies. Since its founding in 2009, PRECISIS has made a name for itself with the EASEE® brain pacemaker, a pioneering and minimally invasive solution for the treatment of epilepsy. The company combines state-of-the-art technology with a deep understanding of the needs of patients and healthcare professionals. With a clear focus on core markets in Europe and the USA, PRECISIS aims to sustainably improve the quality of life for people worldwide. The company is committed to technological innovations that offer early therapeutic options, setting a new standard in neuromodulation.